S-8613

S-8613 is an investigational, orally bioavailable small molecule inhibitor of the voltage-gated sodium channel Nav1.8 (encoded by the SCN10A gene), currently in Phase 1 clinical development by Shionogi. Nav1.8 is a key sodium channel isoform predominantly expressed in peripheral sensory neurons (nociceptors), where it plays a crucial role in the initiation and propagation of action potentials in response to noxious stimuli. By selectively targeting Nav1.8, S-8613 aims to provide potent analgesia for both acute and chronic pain conditions while avoiding the central nervous system (CNS) and cardiovascular side effects typically associated with non-selective sodium channel blockers (which affect Nav1.1, Nav1.2, or Nav1.5) or the addiction risks of opioids. The compound represents a novel non-opioid approach to pain management, addressing a significant unmet need for effective analgesics with improved safety profiles.